Advertisement

U.K. regulator reports 30 blood clot cases linked to AstraZeneca COVID-19 vaccine

Click to play video: 'Dr. Tam explains shifting guidance on AstraZeneca vaccine' Dr. Tam explains shifting guidance on AstraZeneca vaccine
WATCH: Dr. Tam explains shifting guidance on AstraZeneca vaccine – Mar 31, 2021

Britain’s medicines regulator is urging people to continue taking the AstraZeneca coronavirus vaccine, despite revealing that seven people in the U.K. have died from rare blood clots after getting the jab.

The Medicines and Healthcare Regulatory Agency, or MHRA, said it wasn’t clear if the shots are causing the clots, and that its “rigorous review into the U.K. reports of rare and specific types of blood clots is ongoing.”

Though the agency said late Friday that seven people had died as a result of developing blood clots, it didn’t disclose any information about their ages or health conditions.

Read more: AstraZeneca COVID-19 vaccine not recommended for those under 55, NACI says

In total, MHRA said had identified 30 cases of rare blood clot events out of 18.1 million AstraZeneca doses administered up to and including March 24. The risk associated with this type of blood clot is “very small,” it added.

Story continues below advertisement

“The benefits of COVID-19 vaccine AstraZeneca in preventing COVID-19 infection and its complications continue to outweigh any risks and the public should continue to get their vaccine when invited to do so,” said Dr. June Raine, the agency’s chief executive.

Concerns over the AstraZeneca vaccine has already prompted some countries including Canada, France, Germany and the Netherlands to restrict its use to older people. The U.K., which has rolled out coronavirus vaccines faster than other European nations, is particularly reliant on the AstraZeneca vaccine, which was developed by scientists at the University of Oxford.

On Monday, Canada’s National Advisory Committee on Immunization (NACI) reccomended AstraZeneca’s COVID-19 vaccine not be administered to people under the age of 55.

Click to play video: 'EU drug regulator chief says no evidence to support restricting use despite reports of rare blood clotting' EU drug regulator chief says no evidence to support restricting use despite reports of rare blood clotting
EU drug regulator chief says no evidence to support restricting use despite reports of rare blood clotting – Mar 31, 2021

The committee cited concerns over reports of blood clots as its reason for issuing the new guidance.

Story continues below advertisement

In a statement on Monday, Health Canada said in it would be issuing additional “terms and conditions on the authorizations of the AstraZeneca and Verity Pharmaceuticals/Serum Institute of India vaccines.”

This includes a requirement that the manufacturers conduct a “detailed assessment” of the benefits and risks of the vaccine by age and sex in the Canadian context.”

However, in a statement issued Wednesday, the agency said “based on all of the evidence available internationally to date, Health Canada continues to consider that the benefits of the AstraZeneca and COVISHIELD vaccines to protect against COVID-19 outweigh the potential risks.”

The World Health Organization has also urged countries to continue using the jab.

Read more: Concerns around AstraZeneca COVID-19 vaccine, but many still want it

MHRA’s view about the relative benefits of the vaccine is shared by the European Medicines Agency. It has said a causal link between unusual blood clots in people who have had the vaccine is “not proven, but is possible,” and that the benefits of the vaccine outweigh the risks of side effects. The World Health Organization has also urged countries to continue using the jab.

Adam Finn, a professor of pediatrics at the University of Bristol, said the “extreme rarity” of the blood-clotting events in the context of the millions of jabs administered in the U.K. makes the decision facing people very straightforward.

Story continues below advertisement

“Receiving the vaccine is by far the safest choice in terms of minimizing individual risk of serious illness or death,” he said.

A more detailed look at the MHRA’s findings show that of the 30 cases, 22 related to cerebral venous sinus thrombosis, which stops blood draining from the brain properly, and eight were connected with other thrombosis events with low platelets.

It said there were no reports of any blood-clotting events around the Pfizer/BioNTech vaccine, which has also been widely rolled out in the U.K.

— With files from Global News’s Hannah Jackson 

Sponsored content